Unusual clinical presentations of giant prolactinomas

Pituitary

Volumn 14, Issue 4, 2011, Pages 340-344

  Grozinsky Glasberg, Simona ^a,b   Shimon, Ilan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

CSF leak; Giant prolactinomas; Mood changes; Photophobia; Unusual symptoms

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; FOLLITROPIN; GONADOTROPIN; HEMOGLOBIN; KI 67 ANTIGEN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE;

ADULT; ANEMIA; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DIZZINESS; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HEADACHE; HEMIANOPIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; LABORATORY TEST; LIBIDO DISORDER; LIQUORRHEA; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MALE SEXUAL DYSFUNCTION; MOOD DISORDER; NERVE PARALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIMETRY; PHOTOSENSITIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PTOSIS; RHINORRHEA; SCOTOMA; SKULL SURGERY; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL; TRANSSPHENOIDAL SURGERY; VISUAL DISORDER;

ADULT; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; TUMOR BURDEN;

EID: 80053910702     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-008-0160-0     Document Type: Article

References (19)

1. AA Luciano 1999 Clinical presentation of hyperprolactinemia J Reprod Med 44 1085 1090 10649815 1:STN:280:DC%2BD3c7hsVSktw%3D%3D (Pubitemid 30030163)
2. J Sclechte K Dolan B Sherman, et al. 1989 The natural history of untreated hyperprolactinemia: a prospective analysis J Clin Endocrinol Metab 68 412 418 10.1210/jcem-68-2-412 (Pubitemid 19052886)
3. SM Corsello G Ubertini M Altomare, et al. 2003 Giant prolactinomas in men: efficacy of cabergoline treatment Clin Endocrinol (Oxf) 58 622 670 10.1046/j.1365-2265.2003.01770.x 10.1046/j.1365-2265.2003.01770.x (Pubitemid 36566810)
4. RK Shrivastava MS Arginteanu WA King KD Post 2002 Giant prolactinomas: clinical management and long-term follow-up J Neurosurg 97 299 306 12186457 10.3171/jns.2002.97.2.0299 (Pubitemid 34827329)
5. B Velkeniers EL Hooghe-Peters 1998 From prolactin cell to prolactinoma: implications of ontogenic mechanisms in diagnosis and management Endocr Relat Cancer 5 27 36 10.1677/erc.0.0050027 10.1677/erc.0.0050027 1:CAS:528: DyaK1cXjs1alu74%3D (Pubitemid 28168187)
6. I Shimon C Benbassat M Hadani 2007 Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men Eur J Endocrinol 156 225 231 10.1530/EJE-06-0646 17287412 10.1530/EJE-06-0646 1:CAS:528:DC%2BD2sXntlyqu7Y%3D (Pubitemid 46554517)
7. M Kars F Roelfsema JA Romijn AM Pereira 2006 Malignant prolactinoma: case report and review of the literature Aur J Endocrinol 155 523 534 10.1530/eje.1.02268 10.1530/eje.1.02268 1:CAS:528:DC%2BD28XhtFKjtb%2FF (Pubitemid 44636871)
8. MP Gillam ME Molitch G Lombardi A Colao 2006 Advances in the treatment of prolactinomas Endocr Rev 27 485 534 10.1210/er.2005-9998 16705142 10.1210/er.2005-9998 1:CAS:528:DC%2BD28XpvVelurY%3D (Pubitemid 44213229)
9. KS Leong PM Foy AC Swift, et al. 2000 CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas Clin Endocrinol (Oxf) 52 43 49 10.1046/j.1365-2265.2000.00901.x 10.1046/j.1365-2265.2000.00901.x 1:STN:280:DC%2BD3c7ptFKmtw%3D%3D (Pubitemid 30108283)
10. HW Pia H Grote G Hildebrandt 1985 Giant pituitary adenomas Neurosurg Rev 8 207 220 10.1007/BF01815445 2863783 10.1007/BF01815445 1:STN:280: DyaL2M3ps1Omug%3D%3D
11. L Symon J Jakubowski B Kendall 1979 Surgical treatment of giant pituitary adenomas J Neurol Neurosurg Psychiatry 42 973 982 10.1136/jnnp.42.11.973 501374 10.1136/jnnp.42.11.973 1:STN:280:DyaL3c%2FltFaktQ%3D%3D (Pubitemid 10236376)
12. JA Schlechte 2003 Clinical practice. Prolactinoma N Engl J Med 349 2035 2041 10.1056/NEJMcp025334 14627789 10.1056/NEJMcp025334 1:CAS:528: DC%2BD3sXptFKmu7w%3D (Pubitemid 37448927)
13. ME Molitch RL Elton RE Balckwell, et al. 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study J Clin Endocrinol Metab 60 698 705 3882737 10.1210/jcem-60-4-698 1:STN:280:DyaL2M7jtFKiuw%3D%3D (Pubitemid 15147556)
14. P Odin C Oehlwein A Storch, et al. 2006 Efficacy and safety of high-dose cabergoline in Parkinson's disease Acta Neurol Scand 113 18 224 10.1111/j.1600-0404.2005.00514.x 16367894 10.1111/j.1600-0404.2005.00514.x 1:CAS:528:DC%2BD28XislKhtrs%3D
15. R Zanettini A Antonini G Gatto, et al. 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 39 46 10.1056/NEJMoa054830 17202454 10.1056/NEJMoa054830 1:CAS:528: DC%2BD2sXitlCgsQ%3D%3D (Pubitemid 46041752)
16. A Wakil AS Rigby AL Clark, et al. 2008 Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease Eur J Endocrinol 159 R11 R14 10.1530/EJE-08-0365 18625690 10.1530/EJE-08-0365 1:CAS:528:DC%2BD1cXhtlSrtb3O
17. I Ciric M Mikhael T Stafford, et al. 1983 Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results J Neurosurg 59 395 401 6886753 10.3171/jns.1983.59.3.0395 1:STN:280:DyaL3s3ptlGitg%3D%3D (Pubitemid 13048132)
18. JR Davis MC Sheppard DA Heath 1990 Giant invasive prolactinoma: a case report and review of nine further cases Q J Med 74 227 238 2385731 1:STN:280:DyaK3czkvFyhtQ%3D%3D (Pubitemid 20121042)
19. HH Oruckaptan O Senmevsim OE Ozcan T Ozgen 2000 Pituitary adenomas: results of 684 surgically treated patients and review of the literature Surg Neurol 53 211 219 10.1016/S0090-3019(00)00171-3 10773251 10.1016/S0090-3019(00) 00171-3 1:STN:280:DC%2BD3c3jsl2mtw%3D%3D (Pubitemid 30201524)